Released Feb 26, 2021, before the open
10-K filed Feb 26, 2021, 57 days after period end · 0001564590-21-009214
Q4 2020 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$117.62M$117.62M derived−3.2% vs Q4 2019+6.0% vs Q3 2020
Net Income-$9.38M-$9.38M derivedN/M vs Q4 2019N/M vs Q3 2020
EPS, diluted—Not derived. Share counts vary by quarter.
Gross Profitderived$88,548,000−7.1%
Operating Incomederived$3,705,000−9.5%
Operating Cash Flowderived$22,291,000+86.6%
Free Cash Flowderived$18,431,000+175.8%
Margins · derived
Gross margin75.3%−3.2 pt vs Q4 2019
Operating margin3.2%−0.2 pt vs Q4 2019
Net margin-8.0%−17.6 pt vs Q4 2019
What the release said
The release
Same quarter
| Metric | Q4 2020dderived from reported figures | Q4 2019 | Q4 2018 | Q4 2017 |
|---|---|---|---|---|
| Revenue | $117.62M | $121.49M | $121.08M | $116.90M |
| Net Income | -$9.38M | $11.69M | $8.87M | $1.57M |
| EPS Diluted | — | $0.60 | $0.46 | $0.08 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Orthofix Medical Inc. · CIK 884624 · Engraved from SEC EDGAR